Friday, March 22, 2019
Subscribe Successful Calls Model Portfolio Login Free Trial Feedback About Us FAQ Links

Market Digest Online Banner
 
 



[Most Recent Quotes from www.kitco.com]
[Most Recent Quotes from www.kitco.com]



Market Digest Online FRIDAY, MARCH 22, 2019: Stocks rose on Thursday as Apple and Micron surged to lead the tech sector higher. Investor sentiment was also boosted by the Federal Reserve’s updated outlook on interest-rate hikes. The Dow Jones Industrial Average closed 216.84 points higher at 25,962.51 as a 3.7 percent gain in Apple offset a decline of 1.6 percent in J.P. Morgan Chase. The S&P 500 closed 1.1 percent higher at 2,854.88 while the Nasdaq Composite outperformed, rising 1.4 percent to 7,838.96.

Apple rose after Needham upgraded the stock to strong buy from buy, citing "value upside "in the firm's ecosystem. Thursday's gains led the stock to break above its 200-day moving average for the first time since November. Micron shares jumped 9.6 percent after reporting quarterly earnings that beat analyst expectations. Those gains lifted the VanEck Vectors Semiconductor ETF (SMH) by 3.5 percent.

"There's been a lot of buying in the tech sector after some good news," said Ilya Feygin, senior strategist at WallachBeth Capital. "Tech has definitely been the leader. There's been a lot of strength coming from there; I think a lot of that is deployment of cash."

Equities also got a lift as investors largely cheered the latest policy announcement from the Fed. On Wednesday, the Fed said it does not expect to raise rates at all in 2019. The central bank had forecast at least two rate hikes for this year back in December. The Fed added it expects to end its balance-sheet reduction process by the end of September.

Treasury yields fell sharply on Wednesday, with the benchmark 10-year rate hitting its lowest level in a year. The yield traded at 2.53 percent on Thursday while the short-term 2-year rate held at 2.41 percent. Yields move inversely to prices.

"The U.S. economy is on solid ground compared to the rest of the world, said Charlie Ripley, senior investment strategist at Allianz Investment Management. He also said: "While the Fed continues with the wait-and-see policy stance, we think it would require a material deterioration in growth or some exogenous shock to the markets for the Fed to be completely done raising rates in the current cycle."

Biogen tanked more than 29 percent after discontinuing trials for a drug aimed at treating Alzheimer’s Disease. The move sent the iShares MSCI Nasdaq Biotechnolgy ETF (IBB) down 1.1 percent.


© Copyright 1998+ Market Digest Online, Inc. All Rights Reserved